Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Picked Up by Analysts at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) in a report issued on Wednesday, Marketbeat.com reports. The firm set an “overweight” rating and a $87.00 price target on the stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 15.28% from the company’s current price.

Other analysts have also issued research reports about the company. JPMorgan Chase & Co. increased their target price on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Canaccord Genuity Group upped their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, August 13th. Citigroup lifted their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Finally, Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Kiniksa Pharmaceuticals International has an average rating of “Moderate Buy” and an average target price of $93.14.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ KNSA traded down $0.26 during trading on Wednesday, hitting $75.47. The stock had a trading volume of 17,851 shares, compared to its average volume of 682,761. Kiniksa Pharmaceuticals International has a one year low of $35.20 and a one year high of $82.94. The stock has a 50 day simple moving average of $76.56 and a 200 day simple moving average of $61.16. The stock has a market capitalization of $5.89 billion, a price-to-earnings ratio of 77.47 and a beta of 0.09.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, meeting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%.The firm had revenue of $243.60 million for the quarter, compared to analysts’ expectations of $226.49 million. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International will post 1.37 EPS for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 4,600 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total transaction of $369,380.00. Following the transaction, the chief accounting officer directly owned 29,062 shares in the company, valued at $2,333,678.60. This represents a 13.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the transaction, the director owned 11,672 shares in the company, valued at approximately $950,450.96. The trade was a 23.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 51.98% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently modified their holdings of the business. Rubric Capital Management LP raised its stake in Kiniksa Pharmaceuticals International by 12.7% in the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after buying an additional 421,347 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Kiniksa Pharmaceuticals International by 18.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock valued at $39,086,000 after acquiring an additional 128,417 shares in the last quarter. Spruce Street Capital LP boosted its position in Kiniksa Pharmaceuticals International by 75.0% during the 1st quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after acquiring an additional 326,081 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after acquiring an additional 506,576 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in shares of Kiniksa Pharmaceuticals International by 27.3% in the 4th quarter. BNP Paribas Financial Markets now owns 831,777 shares of the company’s stock valued at $34,311,000 after acquiring an additional 178,366 shares during the period. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc (NASDAQ: KNSA) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for patients with debilitating diseases, particularly conditions involving the immune system and inflammation. The company concentrates on areas of significant unmet medical need and uses biologic medicines and other targeted approaches in its research and development programs.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor.